Literature DB >> 12501978

Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.

I Shimon1, D Nass, D J Gross.   

Abstract

We report a case of mixed TSH- and GH-secreting pituitary adenoma in a 60-year-old female patient. She presented with bitemporal hemianopsia and large invasive pituitary macroadenoma. Blood hormone levels determinations revealed elevated thyroid hormones, TSH, and IGF-1 with a relatively low GH. The patient had a mild acromegalic appearance but did not display signs of thyrotoxicosis or goiter. She underwent two pituitary surgical procedures followed by radiotherapy, but despite treatment was still hormonally active. Pathological examination of the resected tumor immunostained positively for both TSH and GH. The patient was subsequently treated with injections of lanreotide, a depot long-acting somatostatin analog, resulting in suppression of blood TSH, thyroid hormones, alpha-subunits, GH and IGF-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12501978     DOI: 10.1023/a:1020706732701

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  20 in total

1.  Clinical and morphological features of undifferentiated monomorphous GH/TSH-secreting pituitary adenoma.

Authors:  T Skorić; M Korsić; K Zarković; V Plavsić; N Besenski; L Breskovac; Z Giljević; J Paladino
Journal:  Eur J Endocrinol       Date:  1999-06       Impact factor: 6.664

2.  Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.

Authors:  A Shimatsu; H Murabe; Y Nakamura; H Mizuta; C Ihara; K Nakao
Journal:  Endocr J       Date:  1999-02       Impact factor: 2.349

Review 3.  Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors.

Authors:  D Le Roith
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

4.  Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.

Authors:  J M Kuhn; S Arlot; H Lefebvre; P Caron; C Cortet-Rudelli; F Archambaud; P Chanson; A Tabarin; M I Goth; J Blumberg; F Catus; S Ispas; P Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

5.  Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization.

Authors:  R V Lloyd; M Cano; W F Chandler; A L Barkan; E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

6.  Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

Authors:  A Gancel; P Vuillermet; A Legrand; F Catus; F Thomas; J M Kuhn
Journal:  Clin Endocrinol (Oxf)       Date:  1994-03       Impact factor: 3.478

7.  Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.

Authors:  P Chanson; B D Weintraub; A G Harris
Journal:  Ann Intern Med       Date:  1993-08-01       Impact factor: 25.391

8.  Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivity.

Authors:  P Beck-Peccoz; G Piscitelli; S Amr; M Ballabio; M Bassetti; G Giannattasio; A Spada; M Nissim; B D Weintraub; G Faglia
Journal:  J Clin Endocrinol Metab       Date:  1986-04       Impact factor: 5.958

9.  Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.

Authors:  R J Comi; N Gesundheit; L Murray; P Gorden; B D Weintraub
Journal:  N Engl J Med       Date:  1987-07-02       Impact factor: 91.245

10.  Effect of a long-acting somatostatin analogue (SMS 201-995) on a growth hormone and thyroid stimulating hormone-producing pituitary tumor.

Authors:  R Hirasawa; K Hashimoto; S Makino; S Suemaru; T Takao; Z Ota; Y Hoshida; T Yoshino; T Akagi
Journal:  Acta Med Okayama       Date:  1991-04       Impact factor: 0.892

View more
  2 in total

1.  Dissociated responsiveness of a growth hormone- and thyrotropin-secreting pituitary adenoma to octreotide-long-acting release therapy: the intriguing case of Mister B.

Authors:  L Curtò; M Ragonese; M Losa; F Trimarchi; S Cannavò
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

2.  TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature.

Authors:  Rosane Ness-Abramof; Avraham Ishay; Gideon Harel; Noa Sylvetzky; Elzbieta Baron; Yona Greenman; Ilan Shimon
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.